Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
COMPARABLE OUTCOMES AFTER BUSULFAN- OR TREOSULFAN-BASED CONDITIONING FOR ALLO-HSCT IN CHILDREN WITH ALL-RESULTS OF FORUM.
Kałwak K, Moser LM, Pötschger U, Bader P, Kleinschmidt K, Meisel R, Dalle JH, Yeşilipek MA, Balduzzi AC, Kriván G, Goussetis E, Staciuk R, Sedlacek P, Pichler H, Svec P, Gabriel M, Güngör T, Bilic E, Buechner J, Renard M, Vettenranta K, Ifversen M, Diaz-de-Heredia C, Stein J, Toporski J, Bierings MB, Peters C, Ansari M, Locatelli F. Kałwak K, et al. Among authors: diaz de heredia c. Blood Adv. 2024 Nov 27:bloodadvances.2024014548. doi: 10.1182/bloodadvances.2024014548. Online ahead of print. Blood Adv. 2024. PMID: 39602342
Prognostic significance of mutation type and chromosome fragility in Fanconi anemia.
Ramírez MJ, Pujol R, Minguillón J, Bogliolo M, Persico I, Cavero D, de la Cal A, Río P, Navarro S, Casado JA, Bailador A, de la Fuente AS, de Heredia ML, Almazán F, Antelo ML, Argilés B, Badell I, Baragaño M, Beléndez C, Bermúdez M, Bernués M, Buedo MI, Carrasco E, Català A, Costa D, Cuesta I, Fernandez-Delgado R, Fernández-Teijeiro A, Figuera Á, García M, Gondra A, González M, Muñiz SG, Hernández-Rodríguez I, Ibañez F, Kelleher NJ, Lendínez F, López M, López-Almaraz R, Marchante I, Mendoza C, Nieto J, Ojeda E, Payán-Pernía S, Peláez I, de Soto IP, Portugal R, Ramos-Arroyo MA, Regueiro A, Rodríguez A, Rosell J, Saez R, Sánchez J, Sánchez M, Senent M, Tapia M, Trujillo-Quintero JP, Vagace JM, Verdú-Amorós J, Verdugo V, Vidales I, Villarreal J, Díaz-de-Heredia C, Sevilla J, Bueren JA, Surrallés J. Ramírez MJ, et al. Among authors: diaz de heredia c. Am J Hematol. 2024 Nov 19. doi: 10.1002/ajh.27520. Online ahead of print. Am J Hematol. 2024. PMID: 39562502
Secondary haematological dysplasia after CAR-T-cell therapy for acute lymphoblastic leukaemia in children.
Theron A, Alonso-Saladrigues A, Dapena JL, López-Duarte M, Diaz de Heredia C, Verdú-Amorós J, Sarrate E, Esperanza-Cebollada E, Cuatrecasas E, Andreu S, Conde N, Sanchez-Sierra N, Isola I, Camós M, Torrebadell M, Rives S, Català A. Theron A, et al. Among authors: diaz de heredia c. Br J Haematol. 2024 Oct 28. doi: 10.1111/bjh.19862. Online ahead of print. Br J Haematol. 2024. PMID: 39463072
Newborn Screening for Sickle Cell Disease in Catalonia between 2015 and 2022-Epidemiology and Impact on Clinical Events.
González de Aledo-Castillo JM, Argudo-Ramírez A, Beneitez-Pastor D, Collado-Gimbert A, Almazán Castro F, Roig-Bosch S, Andrés-Masó A, Ruiz-Llobet A, Pedrals-Portabella G, Medina-Santamaria D, Nadal-Rey G, Espigares-Salvia M, Coll-Sibina MT, Algar-Serrano M, Torrent-Español M, Leoz-Allegretti P, Rodríguez-Pebé A, García-Bernal M, Solà-Segura E, García-Gallego A, Prats-Viedma B, López-Galera RM, Paredes-Fuentes AJ, Pajares García S, Delgado-López G, Blanco-Álvarez A, Tazón-Vega B, Díaz de Heredia C, Mañú-Pereira MDM, Marín-Soria JL, García-Villoria J, Velasco-Puyó P, On Behalf Of The Sickle Cell Disease Newborn Screening Group Of Catalonia. González de Aledo-Castillo JM, et al. Among authors: diaz de heredia c. Int J Neonatal Screen. 2024 Oct 3;10(4):69. doi: 10.3390/ijns10040069. Int J Neonatal Screen. 2024. PMID: 39449357 Free PMC article.
Outcomes of patients undergoing allogeneic haematopoietic stem cell transplantation for congenital amegakaryocytic thrombocytopenia; a study on behalf of the PDWP of the EBMT.
Aldebert C, Fahd M, Galimard JE, Ghemlas IA, Zecca M, Silva J, Mohseny A, Kupesiz A, Hamladji RM, Miranda N, Güngör T, Wynn RF, Merli P, Sundin M, Faraci M, Diaz-de-Heredia C, Burkhardt B, Bordon V, Angoso M, Bader P, Ifversen M, Herrera Arroyo C, Maximova N, Riesco S, Stein J, Dalissier A, Locatelli F, Kalwak K, Dalle JH, Corbacioglu S. Aldebert C, et al. Among authors: diaz de heredia c. Bone Marrow Transplant. 2024 Dec;59(12):1717-1725. doi: 10.1038/s41409-024-02416-x. Epub 2024 Sep 18. Bone Marrow Transplant. 2024. PMID: 39289521
Accurate donor and recipient selection and a short time to transplant offer excellent outcomes in upfront hematopoietic stem cell transplantation from matched unrelated donors for pediatric severe aplastic anemia and refractory cytopenia of childhood. A study of the Spanish Pediatric Group for Hematopoietic Cell Transplantation and Cell Therapy (GETH-TC).
Uria-Oficialdegui ML, Quintero V, Benitez-Carabante MI, Bueno D, Trabazo M, Lopez-Duarte M, Alonso L, Panesso M, Murillo-Sanjuan L, Fuentes C, Gomez G, Gonzalez-Vicent M, Verdu J, Diaz-de-Heredia C. Uria-Oficialdegui ML, et al. Among authors: diaz de heredia c. Bone Marrow Transplant. 2024 Dec;59(12):1773-1776. doi: 10.1038/s41409-024-02406-z. Epub 2024 Sep 3. Bone Marrow Transplant. 2024. PMID: 39227649 No abstract available.
Novel transferrin gene mutations in four new cases of congenital Atransferrinaemia: Functional and diagnostic pathogenicity despite negative bioinformatics.
Romero-Cortadellas L, Ferrer-Cortès X, Calvo-López L, Olivella M, Barqué A, Diaz-de-Heredia C, Moser K, Kleine Budde I, Sanchez M. Romero-Cortadellas L, et al. Among authors: diaz de heredia c. Br J Haematol. 2024 Oct;205(4):1622-1626. doi: 10.1111/bjh.19675. Epub 2024 Jul 31. Br J Haematol. 2024. PMID: 39081172 No abstract available.
Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease: the REACH4 study.
Locatelli F, Kang HJ, Bruno B, Gandemer V, Rialland F, Faraci M, Takahashi Y, Koh K, Bittencourt H, Cleary G, Rosko C, Li X, St Pierre A, Prahallad A, Diaz-de-Heredia C. Locatelli F, et al. Among authors: diaz de heredia c. Blood. 2024 Nov 14;144(20):2095-2106. doi: 10.1182/blood.2023022565. Blood. 2024. PMID: 39046767 Clinical Trial.
Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study.
Locatelli F, Antmen B, Kang HJ, Koh K, Takahashi Y, Kupesiz A, Dias Matos MGA, Chopra Y, Bhat S, Im HJ, Güngör T, Lu MY, Stefanelli T, Rosko C, St Pierre A, Burock K, Smith Y, Sinclair K, Diaz-de-Heredia C. Locatelli F, et al. Among authors: diaz de heredia c. Lancet Haematol. 2024 Aug;11(8):e580-e592. doi: 10.1016/S2352-3026(24)00174-1. Epub 2024 Jul 10. Lancet Haematol. 2024. PMID: 39002551 Clinical Trial.
Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059.
Wu JH, Pennesi E, Bautista F, Garrett M, Fukuhara K, Brivio E, Ammerlaan ACJ, Locatelli F, van der Sluis IM, Rossig C, Chen-Santel C, Bielorai B, Petit A, Starý J, Díaz-de-Heredia C, Rives S, O'Marcaigh A, Rizzari C, Engstler G, Nysom K, Rubio-San-Simón A, Bruno B, Bertrand Y, Brethon B, Rialland F, Plat G, Dirksen U, Sramkova L, Zwaan CM, Huitema ADR. Wu JH, et al. Among authors: diaz de heredia c. Clin Pharmacokinet. 2024 Jul;63(7):981-997. doi: 10.1007/s40262-024-01386-z. Epub 2024 Jun 22. Clin Pharmacokinet. 2024. PMID: 38907948 Free PMC article.
113 results